Successful treatment of late-onset pulmonary hypertension after atrial septal defect operation with macitentan: Our center experience
Open Access
- 1 January 2018
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 2 (1), 001-003
- https://doi.org/10.29328/journal.jprr.1001006
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A Focus on Macitentan in the Treatment of Pulmonary Arterial HypertensionBasic & Clinical Pharmacology & Toxicology, 2018
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle CellsPLOS ONE, 2012
- The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor AntagonistJournal of Medicinal Chemistry, 2012
- Clinical worsening in trials of pulmonary arterial hypertension: results and implicationsCurrent Opinion in Pulmonary Medicine, 2010
- Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor AntagonistThe Journal of pharmacology and experimental therapeutics, 2008
- Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registryInternational Journal of Cardiology, 2007
- Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart diseaseHeart, 2007
- Primary Pulmonary HypertensionThe New England Journal of Medicine, 1997